These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 1981915)

  • 1. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease.
    Rinne JO; Laihinen A; Någren K; Bergman J; Solin O; Haaparanta M; Ruotsalainen U; Rinne UK
    J Neurosci Res; 1990 Dec; 27(4):494-9. PubMed ID: 1981915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease.
    Rinne UK; Laihinen A; Rinne JO; Någren K; Bergman J; Ruotsalainen U
    Mov Disord; 1990; 5(1):55-9. PubMed ID: 2136932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease.
    Rinne JO; Laihinen A; Rinne UK; Någren K; Bergman J; Ruotsalainen U
    Mov Disord; 1993 Apr; 8(2):134-8. PubMed ID: 8474478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
    Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ
    Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
    Antonini A; Schwarz J; Oertel WH; Beer HF; Madeja UD; Leenders KL
    Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
    Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status.
    Sawle GV; Playford ED; Brooks DJ; Quinn N; Frackowiak RS
    Brain; 1993 Aug; 116 ( Pt 4)():853-67. PubMed ID: 8353712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.
    Kaasinen V; Ruottinen HM; Någren K; Lehikoinen P; Oikonen V; Rinne JO
    J Nucl Med; 2000 Jan; 41(1):65-70. PubMed ID: 10647606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects.
    Smith GS; Dewey SL; Brodie JD; Logan J; Vitkun SA; Simkowitz P; Schloesser R; Alexoff DA; Hurley A; Cooper T; Volkow ND
    Am J Psychiatry; 1997 Apr; 154(4):490-6. PubMed ID: 9090335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding.
    Halldin C; Farde L; Högberg T; Hall H; Ström P; Ohlberger A; Solin O
    Int J Rad Appl Instrum B; 1991; 18(8):871-81. PubMed ID: 1839303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
    Dentresangle C; Veyre L; Le Bars D; Pierre C; Lavenne F; Pollak P; Guerin J; Froment JC; Brousolle E
    Mov Disord; 1999 Nov; 14(6):1025-30. PubMed ID: 10584682
    [No Abstract]   [Full Text] [Related]  

  • 15. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.
    Antonini A; Leenders KL; Vontobel P; Maguire RP; Missimer J; Psylla M; Günther I
    Brain; 1997 Dec; 120 ( Pt 12)():2187-95. PubMed ID: 9448574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756.
    Laihinen AO; Rinne JO; Ruottinen HM; Någren KA; Lehikoinen PK; Oikonen VJ; Ruotsalainen UH; Rinne UK
    J Nucl Med; 1994 Dec; 35(12):1916-20. PubMed ID: 7989969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of simple motor performance on regional dopamine release in the striatum in Parkinson disease patients and healthy subjects: a positron emission tomography study.
    Ouchi Y; Yoshikawa E; Futatsubashi M; Okada H; Torizuka T; Sakamoto M
    J Cereb Blood Flow Metab; 2002 Jun; 22(6):746-52. PubMed ID: 12045673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography of brain dopamine D-2 receptors with 11C-raclopride in early Parkinson's disease.
    Laihinen A; Rinne JO; Någren K; Bergman J; Haaparanta M; Solin O; Ruotsalainen U; Rinne UK
    Acta Radiol Suppl; 1991; 376():151. PubMed ID: 1666759
    [No Abstract]   [Full Text] [Related]  

  • 19. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.
    Linazasoro G; Obeso JA; Gómez JC; Martínez M; Antonini A; Leenders KL
    Clin Neuropharmacol; 1999; 22(5):277-80. PubMed ID: 10516878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
    Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
    J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.